Table 2.

Proportion of PwHA who had zero bleeds (second 6-mo study period; FAS and PPAS)

FAS (N = 115)PPAS (N = 95)
FVIII trough level 1% to 3% (n = 57)FVIII trough level 8% to 12% (n = 58)P*FVIII trough level 1% to 3% (n = 52)FVIII trough level 8% to 12% (n = 43)P*
Zero total bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 42 (29-55) 62 (49-75) .055 40 (27-55) 67 (52-81) .015 
Zero spontaneous bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 60 (47-72) 76 (65-88) .101 60 (45-73) 81 (67-92) .038 
Zero spontaneous joint bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 65 (53-77) 85 (75-95) .026 65 (51-78) 91 (78-97) .008 
FAS (N = 115)PPAS (N = 95)
FVIII trough level 1% to 3% (n = 57)FVIII trough level 8% to 12% (n = 58)P*FVIII trough level 1% to 3% (n = 52)FVIII trough level 8% to 12% (n = 43)P*
Zero total bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 42 (29-55) 62 (49-75) .055 40 (27-55) 67 (52-81) .015 
Zero spontaneous bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 60 (47-72) 76 (65-88) .101 60 (45-73) 81 (67-92) .038 
Zero spontaneous joint bleeds        
 Point estimate (95% CI) of proportion of PwHA, % 65 (53-77) 85 (75-95) .026 65 (51-78) 91 (78-97) .008 

P < .05 between treatment arms was considered statistically significant.

Zero bleeds rate was based on intent-to-treat principle.

*

The null hypothesis of independence was tested against a 2-sided alternative by χ2 test with continuity correction.

Close Modal

or Create an Account

Close Modal
Close Modal